Changes and innovations of the 2017 ESC guidelines on dual antiplatelet therapy in coronary artery disease—a review
- 63 Downloads
Duration and compostion of dual antiplatelet therapy has been increasingly changed within the past few years as also indicated in the firmer ESC guidelines. The current manuscript summarizes the most important changes in dual antiplatelet therapy as shown by a recent ESC position paper and offers quick insight into these new developments.
KeywordsDual antiplatelet therapy Acute coronary syndromes Stable coronary artery disease Atrial fibrillation P2Y12-inhibitors
Conflict of interest
H.F. Alber and K. Huber declare that they have no competing interests.
- 1.Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213–60. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the EuropeESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.an Association for Cardio-Thoracic Surgery (EACTS).CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Roffi M, Patrono C, Collet JP, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37(3):267–315. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).CrossRefPubMedGoogle Scholar
- 4.Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2014;35(37):2541–619. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).CrossRefPubMedGoogle Scholar
- 11.Ziada KM, Abdel-Latif AK, Charnigo R, et al. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: a systematic review and meta-analysis of randomized trials. Catheter Cardiovasc Interv. 2016;87(4):722–32.CrossRefPubMedGoogle Scholar
- 17.Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025–34.CrossRefPubMedGoogle Scholar
- 18.Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–77. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).CrossRefPubMedGoogle Scholar